The current study was performed to examine associations between childhood cancer therapies, chronic health conditions, and symptoms of emotional distress in adult survivors of childhood cancer. METHODS: Participants included 5021 adult survivors of childhood cancer (mean age, 32.0 years [standard deviation, 7.6 years] with a time since diagnosis of 23.2 years [standard deviation, 4.5 years]) who completed measures assessing symptoms of anxiety, depression, and posttraumatic stress. Cardiac, pulmonary, and endocrine conditions were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03; grades 1-4). Structural equation modeling was used to examine hypothesized pathways between cancer treatment exposures, chronic health conditions, and symptoms of emotional distress. Multivariable models were used to estimate relative risks (RRs) for associations between chronic health conditions and distress. RESULTS: Survivors with cardiovascular, endocrine, or pulmonary conditions were found to have a significantly higher prevalence of emotional distress symptoms. In path analyses and multivariable models, significant effects were observed between endocrine (b 5 .12 [P 5.002 INTRODUCTION Improvements in survival rates of childhood cancer over the last 50 years have resulted in a growing number of long-term survivors. Current estimates indicate that nearly 400,000 survivors currently are living in the United States.
INTRODUCTION
Improvements in survival rates of childhood cancer over the last 50 years have resulted in a growing number of long-term survivors. Current estimates indicate that nearly 400,000 survivors currently are living in the United States.
1,2 Survivors who have been exposed to potentially toxic cancer-directed therapies in childhood are at an increased risk of developing late health complications. 3, 4 Results from the Childhood Cancer Survivor Study (CCSS) have indicated that adult survivors of childhood cancer have a substantially greater cumulative incidence of a severe, disabling, life-threatening, or fatal health condition by age 50 years compared with siblings (53.6% vs 19.8%). 5 Clinically ascertained data from the St. Jude Lifetime Cohort have suggested the cumulative incidence of chronic health conditions (of any severity) to be 95% by age 45 years, with approximately 56% of 10-year survivors of childhood cancer developing cardiac conditions (95% confidence interval [95% CI], 53.5%-59.2%), 65% developing pulmonary conditions (95% CI, 60.4%-69.8%), and 62% developing endocrine conditions (95% CI, 59.5%-64.6%). 6 Subgroups of adult survivors also are at risk of symptoms of emotional distress. [7] [8] [9] In a longitudinal analysis, survivors who perceived their health status to worsen over time were found to be at risk of increasing symptoms of depression and anxiety. 7 Past studies also have reported that selfperceptions of health status and physical symptoms are associated with psychological distress symptoms in adolescent and young adult survivors [10] [11] [12] ; however, to our knowledge, little information is available to date regarding the link between chemotherapy and radiotherapy (RT) exposure, subsequent chronic health conditions, and emotional distress symptoms in adult survivors of childhood cancer. In non-cancer populations, cardiac conditions including angina, myocardial infarction, and diabetes have been found to be associated with anxiety. 13 Diabetes and pulmonary disease have been associated with depression, 14 with > 40% of individuals with chronic obstructive pulmonary disease reporting symptoms of depression. [15] [16] [17] In this context, we sought to examine potential associations between chronic health conditions and emotional distress symptoms in adult survivors of childhood cancer while accounting for established associations between therapeutic exposures and chronic health morbidities.
MATERIALS AND METHODS

Participants
The CCSS is a multi-institutional, retrospective cohort study with longitudinal follow-up of survivors of childhood cancer recruited from 26 institutions across North America. The Institutional Review Board at each participating institution approved the CCSS protocol, and all participants provided informed consent. Participants in CCSS include those who: 1) were diagnosed with childhood cancer before age 21 years between January 1, 1970 and December 31, 1986; and 2) survived at least 5 years after diagnosis. The baseline survey began in 1994, and subsequent follow-up surveys are conducted every 4 to 5 years. A detailed description of the cohort methodology and study design have been previously reported. 18, 19 For the current analysis, eligibility required that participants self-completed all questionnaires and were at least aged 18 years at the time of Follow-up 2. Survivors were excluded from the study if they reported a neurodevelopmental condition (ie, mental retardation in 252 individuals [2.7%] ). Because stroke is coded as a cardiac condition in the fourth version of the National Cancer Institute Common Terminology Criteria for Adverse Events, participants reporting these events were excluded to ensure that cardiac morbidity consisted of cardiovascular events and not the neurologic consequences of those events (160 participants [1.7%] (Fig. 1) . Compared with nonevaluable participants, participants in the current study were more likely to be female (53.9% vs 43.1%) (see Supporting Information Table 1 ).
Treatment Exposures
Treatment data were obtained from medical records by trained abstractors. Treatment exposures previously associated with chronic health conditions were selected a priori for inclusion in path analysis models. To uphold the integrity of our statistical modeling, cumulative treatment doses were used when at least 20% of the sample received a specific treatment, and were coded as absent or present otherwise. Therefore, cumulative doses of cranial RT (CRT), thoracic RT, anthracyclines, and intravenous methotrexate (measured as the cumulative dose within the first 5 years of treatment) were coded as continuous variables. Intrathecal chemotherapy was measured as the number of methotrexate or cytarabine injections, and bleomycin and corticosteroids were coded as absent or present.
Chronic Health Conditions
Survivors self-reported chronic health conditions, including the date of onset of each condition, at baseline and at subsequent follow-up assessments (Follow-up 1, Followup 4). Only chronic health conditions with a date of onset before the date of assessment of emotional distress symptoms (Follow-up 2) were included in the analysis. Any chronic health conditions reported at Follow-up 4 with a date of onset occurring after the report of emotional distress symptoms at Follow-up 2 were not included in the current analysis. Consequently, the reported date of onset of chronic health conditions preceded the ascertainment of emotional distress symptoms. The severity of cardiac, endocrine, and pulmonary conditions were graded for severity using the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03), 20 using the maximum grade per reported chronic condition for each organ system. Consistent with past CCSS reports, 4,5 the following grading schema was used: mild (grade 1), moderate (grade 2), severe or disabling (grade 3), or life-threatening (grade 4).
Distress Outcomes
Acute symptoms of depression and anxiety (eg, occurring within the past 7 days) were assessed using the Brief Symptom Inventory 18. 21 Using sex-specific normative data, elevated distress was defined as a T-score 63 (highest 10% of the normative population). Posttraumatic stress symptoms (PTSS) were assessed using the Posttraumatic Stress Diagnostic Scale, a 17-item measure of diagnostic symptoms criteria from the Diagnostic and Statistical Manual of Mental Disorders, 4th edition. 22 A positive endorsement of PTSS was defined as at least 1 reexperiencing symptom, at least 3 avoidance symptoms, and at least 2 arousal symptoms. 23, 24 All emotional distress outcomes were assessed at Follow-up 2.
Statistical Analyses
The prevalence of distress symptoms among survivors with and without chronic health conditions was compared using chi-square tests. Path analysis, a type of structural equation modeling, was used to examine the relations among treatment exposures, chronic conditions, and emotional distress outcomes. For each outcome, the analysis began with an a priori hypothesized path model (see Supporting Information Fig. 1 ), with main effects and interaction terms selected based on existing evidence in the literature. 9, [25] [26] [27] [28] [29] [30] The model was expanded by adding clinically meaningful paths 1 at a time with a modification index of 3.6, beginning with the largest index value. The path model was then reduced by removing paths 1 at a time if the absolute value of the standardized coefficient was <0.05 or the path lacked substantive meaning, beginning with the smallest coefficient. Further model reduction was conducted if the path had a P value > .05 or was not substantively significant, beginning with the largest P value. This process was iterative until the following model-fitting criteria were met: the comparative fit index and the Tucker-Lewis index was > 0.95, and the root mean square error of approximation fell to <0.05. 31 To examine the magnitude of associations between chronic health conditions and emotional distress, log-binomial multivariable regression was used to estimate the relative risk (RR) and 95% CI. Exposures included in multivariable models were restricted to significant direct effects of treatment and chronic health conditions identified in our final path models. The path analysis was conducted using Mplus statistical software, and multivariable regression modeling was conducted using SAS statistical software (version 9.3; SAS Institute Inc, Cary, NC).
RESULTS
Survivors were a mean of 8.3 years of age (standard deviation [SD], 5.9 years) at the time of diagnosis, 24.3 years of age (SD, 7.8 years) at baseline, and 32 years of age (SD, 7.6 years) at the time of Follow-up 2 (Table 1) . Approximately two-thirds of the sample received some form of RT (65.0%), with nearly one-third having received CRT (29.0%), and 80% having received chemotherapy.
Prevalence of Chronic Health Conditions and Emotional Distress Symptoms
Approximately 25% of survivors reported having at least 1 cardiac condition (any grade 1-4), 27% reported an endocrine condition, and 17% reported a pulmonary condition (see Supporting Information Tables 2 and 3 ). The prevalence of elevated distress symptoms was found to be higher among survivors with chronic health conditions compared with those without (Table 2) . For example, a greater percentage of survivors with endocrine conditions reported symptoms of depression (13.1% vs 9.8%; P<.001), anxiety (8.0% vs 6.4%; P<.001), and posttraumatic stress (20.9% vs 14.4%; P<.001) compared with survivors without endocrine conditions. The prevalence of emotional distress symptoms by primary childhood cancer diagnosis is shown in Supporting Information Table 4 .
Pathways From Treatment Exposures to Emotional Distress
Depressive symptoms
Positive interaction effects for a higher dose of CRT and a shorter duration of time since diagnosis (P<.001), a higher dose of CRT and a younger age at diagnosis (P<.001), and a higher dose of CRT and male sex (P 5 .027) were found to be associated with a greater likelihood of endocrine conditions. A main effect of higher-dose thoracic RT was found to be associated with endocrine morbidity (P < .001). Bleomycin exposure (P 5 .004), a higher dose of thoracic RT (P<.001), female sex (P 5 .001), younger age at diagnosis (P 5 .004), and a shorter duration of time since diagnosis (P 5 .001) were associated with pulmonary conditions. The presence of endocrine (P 5 .001) and cardiac (P<.001) conditions also contributed to pulmonary disease. Significant direct determinants of depressive symp- (Table 3) .
Anxiety symptoms
A higher dose of thoracic RT, older age at diagnosis, a longer duration of time since diagnosis, and endocrine conditions were found to have direct effects on cardiovascular disease (all P < .001). Bleomycin exposure (P 5 .003), younger age at diagnosis (P 5 .003), a shorter duration of time since diagnosis (P 5 .002), female sex (P 5 .002), and endocrine (P 5 .001) and cardiac (P<.001) conditions were found to have direct effects on pulmonary morbidity. While accounting for the associations between treatment exposures and chronic health conditions, cardiovascular (b 5 .13 [P 5 .001]) and pulmonary (b 5 .15 [P<.001]) conditions were the direct observed determinants of anxiety symptoms.
Posttraumatic stress symptoms
Higher doses of thoracic RT, older age at diagnosis, a longer duration of time since diagnosis, and endocrine morbidity were found to be directly associated with cardiac conditions (all P < .001). Female sex and interactions between a higher dose of CRT and younger age at diagnosis and a higher dose of CRT and a shorter duration of time since diagnosis were associated with endocrine conditions (all P < .001). Bleomycin exposure (P 5 .001), a higher dose of thoracic RT (P<.001), female sex (P<.001), younger age at diagnosis (P 5 .005), and a shorter duration of time since diagnosis (P 5 .002) were found to be associated with pulmonary conditions. Endocrine (P 
DISCUSSION
To the best of our knowledge, although associations between a primary childhood cancer diagnosis and treatment and risk of emotional distress have been well described, the impact of chronic health conditions, which are becoming increasingly prevalent as survivors age through middle adulthood, has not been previously considered. The objective of the current analysis was to identify pathways from childhood cancer treatment and subsequent chronic health conditions to emotional distress in adulthood. The results demonstrated that survivors who develop cardiovascular, endocrine, and/or pulmonary conditions resulting from cancer-directed therapies in childhood are at risk of developing symptoms of depression, anxiety, and posttraumatic stress. These findings demonstrated the cumulative health effects of childhood cancer over the course of one's lifespan, and underscore the importance of long-term follow-up and screening for physical and mental health morbidities. Among survivors of pediatric malignancies, it is well-established that specific treatment exposures in childhood are associated with late health morbidities. Consistent with this literature, the current study results illustrated the cardiotoxic effects of chest-directed RT and anthracycline exposure, 32, 33 and the deleterious effects of CRT on pituitary and endocrine function. 34 Similarly, as expected, an interaction between a higher CRT dose and younger age at diagnosis conferred a greater risk of endocrine conditions. 35 Although we observed an interaction between a higher CRT dose and years since diagnosis, the risk of endocrine conditions decreased with time. For example, in our depression model, at 15 years after diagnosis, the risk of endocrine conditions increased by 54% for every 10-gray increase in CRT. However, by 35 years after diagnosis, this risk was only 21%. This suggests that as follow-up time increased, the strength of the association between CRT dose and endocrine conditions decreased, although the association remained positive.
Important new findings from the current analysis included the identification of several direct effects between late chronic health conditions and emotional distress among cancer survivors. A direct path was observed between pulmonary morbidity and depressive symptoms, with a 40% increased risk of depressive symptoms noted among survivors with pulmonary conditions. This is similar to research in the general population documenting an association between emphysema and chronic bronchitis (the most common pulmonary conditions reported by Abbreviations: 95% CI, confidence interval; PTSS, posttraumatic stress symptoms.
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Cancer February 1, 2017 survivors in the current study) and depressed mood. [12] [13] [14] Similarly, the observed effect of endocrine dysfunction on depression is consistent with research in the general population linking thyroid dysfunction and growth hormone deficiencies with the risk of depression. 36, 37 Both cardiac and pulmonary conditions were associated with an increased risk of anxiety symptoms (50% and 60% increased risk, respectively). Epidemiologic evidence in the general population supports an association between cardiac disease and anxiety, by way of health behaviors, increased hypertension, or the triggering of fatal coronary events. 13 In addition, anxiety has been identified as a risk factor for exacerbations and hospitalizations in cohort studies of patients with chronic obstructive pulmonary disease. 38, 39 It is interesting to note that pulmonary morbidity was the largest determinant of both anxiety and PTSS, which may reflect a shared underlying mechanism given that posttraumatic stress disorder is classified as an anxiety disorder in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition.
22
Although the results of the current study offer valuable new insights into potential sources of emotional distress symptoms in adult survivors of childhood cancer, they should be considered within the context of several limitations. First, chronic health conditions in the current report were assessed by self-report, which may be less sensitive than direct assessment and subsequently result in the misclassification of chronic health status. 6 Second, we were unable to establish temporality between chronic health conditions and emotional distress. Although the date of onset of survivors' reported chronic health conditions preceded the 7-day window of reported emotional distress symptoms, we did not have information regarding the date of onset of emotional distress symptoms. In addition, survivors may have inaccurately reported the date of onset of their health conditions, and therefore we cannot eliminate the possibility that emotional distress symptoms preceded and/or contributed to the development of chronic health conditions. Longitudinal studies may strengthen this evidence base by establishing temporal ordering of chronic health conditions and emotional distress symptoms. Finally, observed effects between specific health conditions and emotional distress outcomes may partially reflect shared symptoms. For example, survivors reporting endocrine dysfunction may be more likely to experience fatigue or low energy, which also is a symptom of depression. Reliance on self-report data for both exposures (chronic health conditions) and outcomes (distress symptoms) introduces the potential for bias from common method variance.
The results of the current study suggest that chronic health conditions that develop decades after the treatment of childhood cancer are associated with emotional distress symptoms in aging adult survivors. These findings provide support for the routine psychological screening of adult survivors with chronic health conditions. Current long-term follow-up guidelines for survivors of childhood cancer recommend screening based on specific therapeutic exposures. 40 The results of the current study suggest that in adulthood, chronic health conditions may serve as a more proximal and reliable indicator of survivors who are in need of psychological screening than treatments received several decades earlier. Alternatively, survivors who received more intensive cancer-directed therapies may be at risk of both chronic health conditions and psychological distress. Ultimately, treatment for distress symptoms will likely involve evidence-based interventions such as cognitive behavioral therapy or pharmacotherapy regardless of etiology. However, screening an at-risk population may facilitate the early identification of distress symptoms and timely intervention before symptoms become chronic and functionally impairing. The current study findings also support a prophylactic approach to the prevention of emotional distress symptoms. Specifically, risk-based screening to identify chronic health conditions is important for this population, 40 because the treatment (including medication management) of physical health conditions may have the potential to offset emotional distress symptoms. However, it also is important to consider that the presence of distress symptoms may adversely affect self-management of chronic disease. [41] [42] [43] Finally, interventions such as physical exercise, with the ability to intervene at multiple levels (eg, reducing both the risk of chronic health conditions and symptoms of emotional distress) are important to consider as direct and/or indirect methods with which to improve overall psychological functioning.
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